• Health Canada cleared an expanded license for Nexstim’s NBS 6, adding diagnostic use and chronic neuropathic pain treatment in Canada.
• The system was previously authorized in Canada for major depressive disorder in 2024.
• The decision broadens NBS 6 commercialization to brain mapping diagnostics alongside its existing depression indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.